CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 16 enrolled
Drug / intervention
Tivantinib +3 moredrug
Likely dose
Tivantinib 360 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01447914
NCT01447914Phase 2Completed
CompareCT.gov

A Phase II Study of the c-Met Inhibitor ARQ 197 in Patients With Relapsed, or Relapsed and Refractory Multiple Myeloma

National Cancer Institute (NCI)·interventional·Posted Oct 6, 2011·Updated Aug 28, 2019

In Brief

A Phase 2 clinical trial evaluating Tivantinib, Diagnostic laboratory biomarker analysis, and 2 other interventions for Refractory Multiple Myeloma. Completed, enrolled 16 participants across 1 site.

Detailed Summary

This phase II trial studies the side effects and how well tivantinib works in treating patients with relapsed, or relapsed and refractory multiple myeloma. Tivantinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRefractory Multiple Myeloma
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedOct 6, 2011
Enrollment StartNov 1, 2011
Primary CompletionMar 1, 2014
Study CompletionApr 1, 2014
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 14.7 years ago

Interventions

Tivantinibdrug

Given at a dose of 360 mg oral (PO) twice daily continuously for each day of every 4-week treatment cycle, which will be taken as three tablets of 120 mg each.

Diagnostic laboratory biomarker analysisother

Correlative studies

Questionnaire administrationother

Ancillary studies

Quality-of-life assessmentprocedure

Ancillary studies